J Immunother Cancer: The efficacy of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma

The efficacy of PD-1 inhibitor neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC) is unclear

The efficacy of PD-1 inhibitor neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC) is unclear

The study included patients with previously untreated, resectable (stage II or III) ESCC

The study included patients with previously untreated, resectable (stage II or III) ESCC

Between January 2020 and September 2020, 37 patients were screened and 23 were enrolled

Twenty patients underwent surgery, all underwent R0 resection, and no surgical delay was observed

Efficacy assessment

Among 23 patients, alopecia was the most common treatment-related AE with an incidence of 82.

Among 23 patients, alopecia was the most common treatment-related AE with an incidence of 82.

 Adverse reactions

Median disease-free survival (DFS) was not reached in the entire cohort of patients who underwent surgery

Median disease-free survival (DFS) was not reached in the entire cohort of patients who underwent surgery

prognostic analysis

In primary tumors, the proportion of patients with high mutational burden and high expression of programmed death ligand 1 (PD-L1) was significantly higher in the PCR group than in the non-PCR group (p=0.

In primary tumors, the proportion of patients with high mutational burden and high expression of programmed death ligand 1 (PD-L1) was significantly higher in the PCR group than in the non-PCR group (p=0.

In conclusion, the study showed that camrelizumab combined with nab-paclitaxel + carboplatin neoadjuvant therapy in patients with resectable ESCC is effective and safe and controllable

Original source:

Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B , Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S, Cheng C.
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
J Immunother Cancer.
2022 Jan;10(1):e003497.
doi : 10.
1136/jitc-2021-003497.
PMID: 35022193.

Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B , Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S, Cheng C.
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
J Immunother Cancer.
2022 Jan;10(1):e003497.
doi : 10.
1136/jitc-2021-003497.
PMID: 35022193.


Leave a message here